Nick Holford

Model Description Language (MDL): A Standard for Modeling and Simulation

Richard Kaye, Andrew C. Hooker, Mats O. Karlsson, 2017, CPT: pharmacometrics & systems pharmacology.

Disease progression and neuroscience

Nick Holford, 2013, Journal of Pharmacokinetics and Pharmacodynamics.

PKPD Model of Interleukin-21 Effects on Thermoregulation in Monkeys—Application and Evaluation of Stochastic Differential Equations

Henrik Madsen, Rune Viig Overgaard, Nick Holford, 2007, Pharmaceutical Research.

Theory‐based pharmacokinetics and pharmacodynamics of S‐ and R‐warfarin and effects on international normalized ratio: influence of body size, composition and genotype in cardiac surgery patients

Nick Holford, Xiao-Liang Ding, Ling Xue, 2017, British journal of clinical pharmacology.

Holford NHG and Sheiner LB “Understanding the Dose-Effect Relationship-Clinical Application of Pharmacokinetic-Pharmacodynamic Models”, Clin Pharmacokin 6:429–453 (1981)—The Backstory

Nick Holford, N. Holford, 2011, The AAPS Journal.

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.

Nick Holford, M. Caligiuri, J. Lecerf, 2006, Blood.

A pharmacokinetic standard for babies and adults.

Nick Holford, N. Holford, B. Anderson, 2013, Journal of pharmaceutical sciences.

Clinical pharmacology = disease progression + drug action

Nick Holford, N. Holford, 2015, British journal of clinical pharmacology.